Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Resiniferatoxin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sorrento Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin
    Sorrento Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin

    07 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/07/2739412/0/en/Sorrento-Therapeutics-Announces-Positive-Phase-2a-Clinical-Trial-Results-for-Resiniferatoxin-RTX-for-the-Treatment-of-Knee-Pain-in-Moderate-to-Severe-Osteoarthritis-of-the-Knee-OAK.html

    GLOBENEWSWIRE
    07 Sep 2023
    Share Share
    Sorrento Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin
    Sorrento Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin

    26 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/26/2522613/0/en/Sorrento-Therapeutics-Completes-Enrollment-of-Phase-2-Clinical-Trial-of-Resiniferatoxin-RTX-for-Treatment-of-Knee-Pain-in-Moderate-to-Severe-Osteoarthritis-of-the-Knee-OAK-Patients.html

    GLOBENEWSWIRE
    26 Sep 2022
    Share Share
    FDA Clears Sorrento Ph 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin
    FDA Clears Sorrento Ph 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin

    06 Jul 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/07/06/2258496/0/en/FDA-Clears-Sorrento-Phase-2-Trial-Of-Non-Opioid-Product-Candidate-Resiniferatoxin-RTX-For-Treatment-of-the-Knee-Pain-in-Osteoarthritis-OA-Patients.html

    GLOBENEWSWIRE
    06 Jul 2021
    Share Share
    Sorrento announces positive results of Epidural Resiniferatoxin injection
    Sorrento announces positive results of Epidural Resiniferatoxin injection

    23 Sep 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=131351&sid=2

    PHARMABIZ
    23 Sep 2020
    Share Share
    Sorrento Therapeutics Releases Positive Results of Resiniferatoxin (RTX) Trial
    Sorrento Therapeutics Releases Positive Results of Resiniferatoxin (RTX) Trial

    22 Sep 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/09/22/2097558/0/en/Sorrento-Therapeutics-Releases-Positive-Results-of-Phase-1B-Trial-of-Resiniferatoxin-RTX-Epidural-in-Cancer-Patients-with-Reported-Intractable-Pain.html

    GLOBENEWSWIRE
    22 Sep 2020
    Share Share
    Sorrento to Present Late Breaking +ve Clinical Trial Data for Resiniferatoxin
    Sorrento to Present Late Breaking +ve Clinical Trial Data for Resiniferatoxin

    27 Jan 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/01/27/1975330/0/en/Sorrento-to-Present-Late-Breaking-Positive-Clinical-Trial-Data-for-Resiniferatoxin-at-Two-Prestigious-Upcoming-Pain-Conferences.html

    GLOBENEWSWIRE
    27 Jan 2020
    Share Share